ReviewGeriatrics & gerontology international2026
Further Insights Into Anticholinergic Action Informed by Japanese Anticholinergic Risk Scale.
Review in Geriatrics & gerontology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Further Insights Into Anticholinergic Action Informed by Japanese Anticholinergic Risk Scale.Geriatrics & gerontology international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increased anticholinergic burden caused by medications in older adults is one of the adverse drug reactions of particular concern, as it can exacerbate the onset of geriatric syndromes or induce cognitive dysfunction, and is also related to the issue of polypharmacy. One year has passed since the "Japanese Anticholinergic Risk Scale" was published by the Japanese Society of Geriatric Pharmacy, and the anticholinergic effects of various medications have garnered attention. These medications are used in clinical practice and research. The anticholinergic effects of drugs are not necessarily induced solely by binding to muscarinic receptors and exerting antagonistic actions but may also occur as a result of various combined effects. In this review, we focus on drugs that show differences between the "Yamada Classification," which was created based on in vitro muscarinic receptor binding activity, and the "Japanese Anticholinergic Risk Scale." We re-examine anticholinergic effects and, through a review of the literature, identify drugs that induce "anticholinergic-like effects" beyond direct muscarinic receptor antagonism. By understanding the potential mechanisms underlying "anticholinergic-like effects" in drugs where anticholinergic effects listed in the risk scale are not anticipated, we aim to reemphasize the prevalence of drugs with anticholinergic-like effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.